new drug in front of Bronchiolitis In Castile and Leon.Castilla Leon will combine immunoprophylaxis with the drug Nisevumab For children born between March 1, 2023, and March 31, 2024, prevent respiratory syncytial virus (RSV) by administering a single dose of the above monoclonal antibodies during the next RSV transmission season (2023-2024).Health will distribute 500 doses in Soria Province The aim is to immunize as many babies as possible.
The company also assumes Change the name of the current calendarFrom “vaccination” to “a lifetime immunization calendar for people”, as the military government of Castile and León has just announced.
Respiratory syncytial virus production common viral diseases This usually causes mild cold-like symptoms.but it may result in severe respiratory infection Lower legs and lungs, especially bronchiolitis and pneumonia, especially in infants but also in the elderly and people with chronic diseases.
Thus, bronchiolitis is a Parents care about their baby, there is nothing unfounded, as many small children end up being admitted.The health department estimates that Castile and León will be immunized around October-October 13,000 children.
he RSV can affect people of all ages and is very common in young childrenMore than 90% of minors are infected by age 2, resulting in a high disease burden in childhood and a season of overloaded primary care and hospital care during viral transmission.
this Greater burden concentrated in children under 6 monthsin general, RSV infection occurs in autumn or winter, so this seasonality means that the incidence of RSV higher hospitalization rate Occurs more in people born in autumn and winter.
Currently, there is a new drug that provides passive immunity against RSV.It is nirsevimab, a Monoclonal antibodies (a laboratory-produced molecule intended as a surrogate that can alter or mimic immune system attack) for the prevention of RSV lower respiratory disease in children under 12 months of age during the first season against RSV.proposed a Good safety and efficacy The long half-life provides protection for at least 5 months after administration.
For all these reasons, a single dose of nirsevimab administered during the campaign 2023-2024 is included in the lifelong immunization schedule for children born between March 1, 2023 and March 31, 2024 in Castile and León middle.
depends on date of birth Administration will take place in a hospital or health center, as follows:
- Those born on or after October 1 will receive the monoclonal antibody at the hospital at birth.
- For those born between March and September, there will be a specific campaign at the beginning of the RSV season (expected during October) to give the vaccine either at a health center or at the usual vaccination centre.
- In addition, nirsevimab will be used in pediatric populations at high risk for severe RSV disease, including:
- Preterm infants less than 35 weeks (including premature infants with a gestational age less than 29 weeks), a single dose before 12 months of age.
- Patients with congenital heart disease who are hemodynamically significantly compromised (hypoxic blood) or acyanotic.
- People with bronchopulmonary dysplasia, a condition that affects newborns born on a ventilator or born prematurely.
- Patients with other underlying medical conditions at high risk for severe RSV bronchiolitis, such as severely immunosuppressed patients (neoplastic hematological disorders; primary immunodeficiency, especially combined and congenital agammaglobulinemia; ongoing immunosuppression drug therapy), inborn errors of metabolism, severe neuromuscular or pulmonary disease, genetic syndromes with associated respiratory problems, Down syndrome, cystic fibrosis, and palliative care patients.
- For patients with risk status b, c, and d, nirsevimab will be administered before each RSV season and before turning 24 months at the time of immunization.
number of doses
The dose required to carry out the activity has been calculated Based on the number of children who may have benefited from nirsevimab during the first season of exposure In contrast, VRS refers to children born in Castile and León between March 1, 2023, and March 31, 2024, an estimated 13,000 children.
Distribution in each province
The dose distribution of Nirelizumab by province is as follows:
The total number of vaccines in Castile and Leon is 13,000 doses. A total of 2,825,680 euros will be invested in this campaign to guarantee this new healthcare benefit offered by the military government of Castile and León.